MAZEMaze Therapeutics, Inc.
Health Care
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents revised up 0.6% for Q1 2024
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Q1 2024
As reported
$196.8MRestated
$197.9M0.6%
Verify against SEC filingsShow
As reported$196.8M
Accepted 2025-05-140000950170-25-071375
Restated$197.9M
Accepted 2026-05-120001193125-26-219430
CashAndEquivalents · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get an alert the next time MAZE — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.